Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds
27 juil. 2020 13h15 HE
|
Biofrontera AG
Leverkusen, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Supervisory...
Biofrontera reports preliminary unaudited sales revenue for the first six months of 2020
14 juil. 2020 06h08 HE
|
Biofrontera AG
Leverkusen, Germany, July 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical...
Biofrontera confirms financing need
30 juin 2020 08h30 HE
|
Biofrontera AG
Leverkusen, Germany, June 30, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today confirmed the...
Results of the 2020 Annual General Meeting of Biofrontera AG
28 mai 2020 11h36 HE
|
Biofrontera AG
Leverkusen, Germany, May 28, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, an international...
Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court
13 mai 2020 04h00 HE
|
Biofrontera AG
Leverkusen, Germany, May 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical company, today...
Biofrontera announces conference call to be held on May 20, 2020 to discuss first quarter 2020 financial results
12 mai 2020 11h00 HE
|
Biofrontera AG
Leverkusen, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera AG enters into exclusive license agreement with Maruho Co., Ltd.
20 avr. 2020 04h20 HE
|
Biofrontera AG
Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, has...
Biofrontera reports preliminary unaudited sales revenue for the first three months of 2020
17 avr. 2020 05h15 HE
|
Biofrontera AG
Leverkusen, Germany, April 17, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting
16 avr. 2020 10h00 HE
|
Biofrontera AG
Leverkusen, Germany, April 16, 2020 (GLOBE NEWSWIRE) -- The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the Company...
Biofrontera AG extends subscription period for mandatory convertible bonds
12 mars 2020 13h53 HE
|
Biofrontera AG
Leverkusen, Germany, March 12, 2020 (GLOBE NEWSWIRE) -- On February 26, 2020, Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds...